EGFR+ NSCLC Combination Therapies Improve Outcomes, But Individual Patient Factors Crucial for Selection

A panelist reported that combining therapies for EGFR-positive non–small cell lung cancer (NSCLC) leads to increased benefits alongside increased adverse effects. The reported benefits include improved progression-free survival, higher response rates, and a longer duration of response. Treatment selection, the panelist noted, should consider individual patient characteristics. Specifically, the panelist highlighted the importance of considering factors such as the presence of central nervous system (CNS) metastases, the patient’s performance status, their preferences regarding treatment aggressiveness, and real-world limitations. These limitations arise because patients often differ from those enrolled in clinical trials. The differences can include organ dysfunction, the use of concomitant medications, and a history of previous treatments.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Related posts:

Virginia’s Insurance Marketplace Extends Open Enrollment Deadline: A Detailed Report Cryptic Antigen Identified as New Immunotherapy Target for Ovarian Cancer Groundbreaking Study Reveals How Aging Heart Influences Brain Function Imaging Discovery Promises Faster Drug Development

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後